Tech Company Financing Transactions

Scarlet Therapeutics Funding Round

Scarlet Therapeutics, based in Bristol, secured investment from Meltwind Advisory and Science Creates Ventures.

Transaction Overview

Announced On
5/23/2023
Transaction Type
Amount
Unknown
Round
Seed
Proceeds Purpose
The company intends to use the funds to advance development of its platform and build a pipeline of novel therapies to treat rare diseases.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Science Creates Old Market Midland Rd
Bristol, BS2 0JZ
UK
Phone
Undisclosed
Email Address
Overview
Scarlet Therapeutics is developing a unique platform that generates novel red blood cell-based therapeutics to potentially treat a wide range of diseases. Initially targeted at the rare metabolic diseases, hyperammonemia and hyperoxaluria, this approach could also be used more broadly to target other metabolic diseases, cancer and autoimmune diseases. These therapeutic red blood cells (tRBCs) are very similar to standard red blood cells, having many unique qualities compared to systemic administration of therapeutic protein, including pervasive reach throughout the body, a long life and the ability to carry the active proteins within the tRBC, thereby shielding them from the immune system. Born out of more than a decade of research at the University of Bristol and its learnings from the RESTORE clinical study, Scarlet also has an exclusive commercial licence for the widely used BEL-A cell line, which provides an alternative platform technology for production of red blood cells.
Profile
Scarlet Therapeutics LinkedIn Company Profile
Social Media
Scarlet Therapeutics Company Twitter Account
Company News
Scarlet Therapeutics News
Facebook
Scarlet Therapeutics on Facebook
YouTube
Scarlet Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Alistair Irvine
  Alistair Irvine LinkedIn Profile  Alistair Irvine Twitter Account  Alistair Irvine News  Alistair Irvine on Facebook
Chief Scientific Officer
Ash Toye
  Ash Toye LinkedIn Profile  Ash Toye Twitter Account  Ash Toye News  Ash Toye on Facebook
Chief Technical Officer
Jan Frayne
  Jan Frayne LinkedIn Profile  Jan Frayne Twitter Account  Jan Frayne News  Jan Frayne on Facebook


 

 

Browse more venture capital transactions:

Prev: 5/23/2023: Datasembly venture capital transaction
Next: 5/23/2023: Ariadne venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary